How were Dicerna Pharmaceuticals' earnings last quarter?

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) announced its quarterly earnings results on Tuesday, November, 9th. The biopharmaceutical company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.41) by $0.19. The biopharmaceutical company had revenue of $62.95 million for the quarter, compared to analyst estimates of $58.83 million. Dicerna Pharmaceuticals had a negative trailing twelve-month return on equity of 103.08% and a negative net margin of 64.53%. During the same quarter in the prior year, the company earned ($0.29) earnings per share.

What is Douglas M. Fambrough, Ph.D.'s approval rating as Dicerna Pharmaceuticals' CEO?

35 employees have rated Dicerna Pharmaceuticals Chief Executive Officer Douglas M. Fambrough, Ph.D. on Glassdoor.com . Douglas M. Fambrough, Ph.D. has an approval rating of 99% among the company's employees. This puts Douglas M. Fambrough, Ph.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Dicerna Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Dicerna Pharmaceuticals investors own include Axsome Therapeutics (AXSM) , Strongbridge Biopharma (SBBP) , Amarin (AMRN) , Exelixis (EXEL) , Sorrento Therapeutics (SRNE) , TG Therapeutics (TGTX) , Arbutus Biopharma (ABUS) , Gilead Sciences (GILD) , Pfizer (PFE) and Advanced Micro Devices (AMD) .

NASDAQ:DRNA

Dicerna Pharmaceuticals (DRNA) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free DRNA Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $38.22
▼
$38.22
50-Day Range: $37.81
▼
$38.25
52-Week Range: $19.06
▼
$40.14

Volume: N/A
Average Volume: 1.34 million shs
Market Capitalization: $2.99 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Dicerna Pharmaceuticals alerts:

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About Dicerna Pharmaceuticals Stock (NASDAQ:DRNA)

Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson, and John J. Rossi in October 2006 and is headquartered in Lexington, MA.

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

DRNA Stock News Headlines

May 25, 2023 | fool.com

Arrowhead Pharmaceuticals (NASDAQ: ARWR)

February 16, 2023 | thestreet.com

'Mad Money' Lightning Round: I'm Staying Away From Five Below

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

February 7, 2023 | benzinga.com

BiondVax Pharmaceuticals Stock (NASDAQ:BVXV), Quotes and News Summary

January 26, 2023 | marketwatch.com

Myc Proto-Oncogene Protein Market 2023 Statistics, Industry Share, Latest Trends, Growth Drivers, Size Estimate and Forecast till 2028

January 19, 2023 | finance.yahoo.com

We Think Clarity Pharmaceuticals (ASX:CU6) Can Easily Afford To Drive Business Growth

January 14, 2022 | ca.finance.yahoo.com

DRNA Jul 2022 40.000 call(CONTR

January 14, 2022 | ca.finance.yahoo.com

DRNA Jan 2022 22.500 call

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

December 28, 2021 | finance.yahoo.com

Novo Nordisk Announces Completion of Dicerna Pharmaceuticals Acquisition

November 19, 2021 | prnewswire.com

DICERNA INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Dicerna Pharmaceuticals, Inc. - DRNA

November 19, 2021 | finance.yahoo.com

SHAREHOLDER ALERT: WeissLaw LLP Investigates Dicerna Pharmaceuticals, Inc.

November 18, 2021 | finance.yahoo.com

DICERNA ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of DRNA and Encourages Investors to Contact the Firm

November 18, 2021 | finance.yahoo.com

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Sale of Dicerna Pharmaceuticals, Inc. to Novo Nordisk

November 18, 2021 | finance.yahoo.com

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Dicerna Pharmaceuticals, Inc.

November 18, 2021 | barrons.com

Dicerna Stock Skyrockets as Novo Nordisk to Buy Research Partner for $3.3 Billion

November 18, 2021 | finance.yahoo.com

UPDATE 3-Denmark's Novo Nordisk to buy Dicerna Pharma for $3.3 billion

November 12, 2021 | finance.yahoo.com

Dicerna Presents Data From Phase 1 Trial of Belcesiran at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2021

November 12, 2021 | finance.yahoo.com

Dicerna Announces Two Targets Meet Preclinical Proof of Principle Criteria in Neurodegeneration and Pain Under Global Research Collaboration and Licensing Agreement With Lilly

November 10, 2021 | benzinga.com

Dicerna Pharmaceuticals's Return On Capital Employed Overview

November 9, 2021 | sfgate.com

Dicerna Pharmaceuticals: Q3 Earnings Snapshot

November 9, 2021 | finance.yahoo.com

Dicerna Announces Third Quarter 2021 Financial Results and Provides a Business Update

November 4, 2021 | finance.yahoo.com

Dicerna Presents PHYOX™2 and Primary Hyperoxaluria Healthcare Utilization Data at American Society of Nephrology (ASN) Kidney Week 2021

October 18, 2021 | finance.yahoo.com

Hedge Fund Sentiment Is Stagnant On Dicerna Pharmaceuticals Inc (DRNA)

October 15, 2021 | finance.yahoo.com

Dicerna Announces Data to Be Presented at American Society of Nephrology (ASN) Kidney Week 2021

October 14, 2021 | benzinga.com

Dicerna Highlights Will Give Poster Presentations At American Association For Study Of Liver Nov. 12-15, 2021

October 14, 2021 | finance.yahoo.com

Dicerna Announces Poster Presentations at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2021 in November

See More Headlines

Receive DRNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dicerna Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/09/2021
Today: 4/18/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical Preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:DRNA
CUSIP: N/A
CIK: 1399529
Web: www.dicerna.com
Phone: (617) 621-8097
Fax: 617-612-6298
Employees: 302
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($1.63)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-112,750,000.00
Net Margins: -64.53%
Pretax Margin: -63.82%
Return on Equity: -103.08%
Return on Assets: -16.58%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.46
Quick Ratio: 2.46

Sales & Book Value

Annual Sales: $164.31 million
Price / Sales: 18.17
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.84 per share
Price / Book: 20.77

Miscellaneous

Outstanding Shares: 78,129,000
Free Float: 70,160,000
Market Cap: $2.99 billion
Optionable: Optionable
Beta: 0.80

These 7 Stocks Will Be Magnificent in 2024

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

Douglas M. Fambrough
President, Chief Executive Officer & Director
James B. Weissman
Chief Operating Officer & Executive Vice President
Douglas W. Pagán
Chief Financial Officer
Bob D. Brown
Chief Scientific Officer
Shreeram Aradhye
Chief Medical Officer & Executive Vice President

Key Competitors

View All Competitors

DRNA Stock Analysis - Frequently Asked Questions

How were Dicerna Pharmaceuticals' earnings last quarter?: Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) announced its quarterly earnings results on Tuesday, November, 9th. The biopharmaceutical company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.41) by $0.19. The biopharmaceutical company had revenue of $62.95 million for the quarter, compared to analyst estimates of $58.83 million. Dicerna Pharmaceuticals had a negative trailing twelve-month return on equity of 103.08% and a negative net margin of 64.53%. During the same quarter in the prior year, the company earned ($0.29) earnings per share.
What is Douglas M. Fambrough, Ph.D.'s approval rating as Dicerna Pharmaceuticals' CEO?: 35 employees have rated Dicerna Pharmaceuticals Chief Executive Officer Douglas M. Fambrough, Ph.D. on Glassdoor.com. Douglas M. Fambrough, Ph.D. has an approval rating of 99% among the company's employees. This puts Douglas M. Fambrough, Ph.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Dicerna Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Dicerna Pharmaceuticals investors own include Axsome Therapeutics (AXSM), Strongbridge Biopharma (SBBP), Amarin (AMRN), Exelixis (EXEL), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Arbutus Biopharma (ABUS), Gilead Sciences (GILD), Pfizer (PFE) and Advanced Micro Devices (AMD).

This page (NASDAQ:DRNA) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Dicerna Pharmaceuticals (DRNA) Stock Price, News & Analysis

About Dicerna Pharmaceuticals Stock (NASDAQ:DRNA)

DRNA Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

DRNA Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info